CA073-1003
Golseek-4

Phase III

A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) Vs Investigator’s Choice in Participants with Relapsed/Refractory Follicular Lymphoma

 Eudract Nr. 2024-519152-82

CLEAR

II

Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

EU-CT-Nummer:  2023-509861-19-01

BGB-16673-104

Ib/II

A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies

EU-CT-Nummer:  2024-516234-35

Soundtrack-B

D7404C00001

II

Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients

EU-CT-Nummer: 2023-505789-27